Exclusive live coverage from day one of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
ASCO 2019 kicks off this year with a strong focus on prostate cancer, as several pharma companies are attempting to find ways to treat the disease earlier, or find better ways to prevent it spreading.
Key readouts to look for on Friday 31st May:
- Data from Johnson & Johnson’s Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC). This will be the first time that we get the chance to see detailed data from the phase 3 TITAN study.
- AstraZeneca and Merck & Co have data from the phase 2 TOPARB-B trial, testing their PARP inhibitor Lynparza (olaparib) for metastatic castration resistant prostate cancer.
- AstraZeneca and Merck & Co are also due to present data from a phase 3 study testing Lynparza in pancreatic cancer, in patients with an inherited BRCA gene mutation.
View the live coverage from day one at ASCO 2019 below (the live blog may take a few seconds to load) and we will also have live coverage from day two at ASCO:
Dominic_Tyer
And that’s it for our live coverage of day one at ASCO 2019, presented in association with Kantar Health.
We’ll be back tomorrow with expanded news coverage of some of today’s key events as well as a live blog from day two of ASCO 2019.
In the meantime if you are on site tomorrow there’s an interesting looking session on social media for authors from 2-3pm.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.